Company performance
Current Price
as of Jan 23, 2025$10.20
P/E Ratio
N/A
Market Cap
$865.12M
Description
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Metrics
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryBiotechnology
- TickerAVXL
- Price$10.2+2.10%
Trading Information
- Market cap$865.12M
- Float96.82%
- Average Daily Volume (1m)2,527,806
- Average Daily Volume (3m)1,994,777
- EPS-$0.52
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$43.00M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$52.88M
- EV$341.91M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B7.19
Documents
SEC Filings
Factset Street Account